Perrigo to sell HRA Pharma Rare Diseases to Esteve for up to €275M

PERRIGO Co plc

Total consideration up to €275M: €190M cash plus up to €85M earnout on sales milestones.
Esteve Healthcare signed binding offer; Perrigo has a put option to finalize sale.
Transaction expected to close in Q3 2024, subject to Works Council consultation and regulatory approvals.
Sale includes HRA Pharma Rare Diseases business; Perrigo will proceed after French Works Council process.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.